|
1
|
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
|
J Clin Oncol
|
2006
|
7.43
|
|
2
|
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
|
JAMA
|
2008
|
7.07
|
|
3
|
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
|
J Clin Oncol
|
2012
|
4.48
|
|
4
|
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
|
J Clin Oncol
|
2005
|
3.50
|
|
5
|
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.
|
J Clin Oncol
|
2002
|
3.25
|
|
6
|
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence.
|
Ann Intern Med
|
2003
|
3.01
|
|
7
|
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
|
Int J Radiat Oncol Biol Phys
|
2011
|
2.54
|
|
8
|
Impact of diabetes mellitus on outcomes in patients with colon cancer.
|
J Clin Oncol
|
2003
|
2.52
|
|
9
|
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
|
Ann Surg Oncol
|
2011
|
2.38
|
|
10
|
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.
|
J Clin Oncol
|
2005
|
2.19
|
|
11
|
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
|
Cancer
|
2003
|
2.19
|
|
12
|
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
|
J Clin Oncol
|
2005
|
2.17
|
|
13
|
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
|
J Clin Oncol
|
2007
|
2.00
|
|
14
|
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
|
J Clin Oncol
|
2006
|
1.89
|
|
15
|
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
|
J Clin Oncol
|
2004
|
1.86
|
|
16
|
Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment.
|
Ann Surg Oncol
|
2002
|
1.81
|
|
17
|
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.
|
Ann Intern Med
|
2002
|
1.75
|
|
18
|
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer.
|
J Natl Cancer Inst
|
2002
|
1.38
|
|
19
|
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.27
|
|
20
|
Gastric cancer--new therapeutic options.
|
N Engl J Med
|
2006
|
1.20
|
|
21
|
Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
|
J Clin Oncol
|
2005
|
1.19
|
|
22
|
Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma.
|
Cancer
|
2005
|
1.13
|
|
23
|
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
|
Invest New Drugs
|
2006
|
1.00
|
|
24
|
Impact of hospital volume on recurrence and survival after surgery for gastric cancer.
|
Ann Surg
|
2007
|
0.99
|
|
25
|
Gastric cancer: Nagoya is not New York.
|
J Clin Oncol
|
2011
|
0.95
|
|
26
|
A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.
|
Jpn J Clin Oncol
|
2005
|
0.93
|
|
27
|
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.
|
Invest New Drugs
|
2004
|
0.86
|
|
28
|
Gastric cancer: D2 dissection or low Maruyama Index-based surgery--a debate.
|
Surg Oncol Clin N Am
|
2007
|
0.86
|
|
29
|
Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
|
Oncologist
|
2008
|
0.82
|
|
30
|
Vive la difference: sex and fluorouracil toxicity.
|
J Clin Oncol
|
2002
|
0.81
|
|
31
|
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.
|
Invest New Drugs
|
2006
|
0.81
|
|
32
|
Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.81
|
|
33
|
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
|
Invest New Drugs
|
2002
|
0.78
|
|
34
|
Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.
|
J Clin Oncol
|
2003
|
0.76
|
|
35
|
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
|
Clin Colorectal Cancer
|
2005
|
0.76
|
|
36
|
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
|
Am J Clin Oncol
|
2010
|
0.75
|
|
37
|
Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.
|
Pancreas
|
2016
|
0.75
|
|
38
|
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study.
|
Invest New Drugs
|
2002
|
0.75
|
|
39
|
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
|
Invest New Drugs
|
2004
|
0.75
|
|
40
|
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
|
Invest New Drugs
|
2004
|
0.75
|